Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Personalis, Inc.

Market Cap 100.64Cr 87Cr 80Cr 75Cr 140.18Cr 9.59TCr 143.33Cr 953.99Cr 369.97Cr 4.64TCr 377.77Cr 369.66Cr 16TCr P/E Ratio 2026 *
-9.4x
P/E Ratio 2027 * -10.7x
Enterprise Value 85Cr 73Cr 67Cr 63Cr 117.79Cr 8.06TCr 120.43Cr 801.6Cr 310.87Cr 3.9TCr 317.43Cr 310.61Cr 14TCr EV / Sales 2026 *
10.7x
EV / Sales 2027 * 8.35x
Free-Float
72.96%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-10.85%
Current month-15.70%
1 month+60.70%
3 months+15.64%
6 months+3.67%
Current year+20.73%
1 week 9.08
Extreme 9.08
11.95
1 month 5.7
Extreme 5.7
12.53
Current year 4.96
Extreme 4.955
12.53
1 year 3.84
Extreme 3.84
12.53
3 years 0.89
Extreme 0.8906
12.53
5 years 0.89
Extreme 0.8906
28.47
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
President 55 13/03/2026
Chief Executive Officer 65 31/12/2022
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap.
04/06Fiscal year

Chief Financial Officer

1,20,000 0.1353%
29/05Fiscal year

Chief Financial Officer

1,16,397 0.1313%
29/05Fiscal year

Chief Executive Officer

2,40,273 0.2710%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-10.85%+73.78%+338.81% 100.64Cr
-0.13%+1.12%-13.85%-11.52% 4.37TCr
+0.60%-7.56%+243.47%+464.57% 3.07TCr
-0.96%+0.07%+14.02%-11.82% 3.04TCr
-3.44%-8.12%-1.99%+20.64% 2.93TCr
-1.59%-6.51%+8.30%+13.51% 2.42TCr
+0.49%+3.31%+52.25%+124.06% 1.33TCr
+0.53%-3.23% - - 1.3TCr
+0.31%+0.83%+10.00%+10.11% 1.32TCr
-0.20%-0.68%+101.46%+75.14% 1.21TCr
Average -0.64%-2.17%+54.16%+113.72% 2.11TCr
Weighted average by Cap. -0.77%-1.74%+48.31%+87.66%

Financials

2026 *2027 *
Net sales 7.87Cr 6.82Cr 6.28Cr 5.88Cr 11Cr 750.19Cr 11Cr 75Cr 29Cr 363.31Cr 30Cr 29Cr 1.26TCr 11Cr 9.61Cr 8.86Cr 8.29Cr 15Cr 1.06TCr 16Cr 105.24Cr 41Cr 512.2Cr 42Cr 41Cr 1.78TCr
Net income -11Cr -9.26Cr -8.54Cr -7.99Cr -15Cr -1.02TCr -15Cr -101.44Cr -39Cr -493.7Cr -40Cr -39Cr -1.72TCr -9.64Cr -8.34Cr -7.69Cr -7.2Cr -13Cr -918.38Cr -14Cr -91Cr -35Cr -444.76Cr -36Cr -35Cr -1.55TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.53TCr -23Cr -152.38Cr -59Cr -741.67Cr -60Cr -59Cr -2.58TCr -7.98Cr -6.91Cr -6.37Cr -5.96Cr -11Cr -760.54Cr -11Cr -76Cr -29Cr -368.32Cr -30Cr -29Cr -1.28TCr
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
11/26/11 9.665 $ +0.57% 60,413
10/26/10 9.610 $ -1.44% 20,20,968
09/26/09 9.750 $ -2.89% 40,11,394
08/26/08 10.04 $ -6.60% 23,41,661
05/26/05 10.75 $ -11.16% 41,48,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.610USD
Average target price
10.86USD
Spread / Average Target
+12.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!